- Recruiting
NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Updated: May 26, 2022
NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT04025216
Official Title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
First Posted : July 18, 2019
Click here to see details on ClinicalTrials.gov
Biological: CART-TnMUC1
Drug: Cyclophosphamide
Drug: Fludarabine
Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes
Autologous Tn-MUC1-specific CAR T-lymphocytes (Code C165433)
Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes
Autologous Anti-TnMUC1-CAR-expressing T-lymphocytes
Autologous CART-TnMUC1 Cells
Autologous Tn-MUC1-specific CAR T Cells
Autologous Tn-MUC1-specific CAR T-lymphocytes
Autologous TnMUC1-targeted Genetically-Modified CAR T Cells
Locations
United States, Arizona
United States, California
United States, Florida
United States, Illinois
United States, Missouri
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Washington